Clinical outcome of 30 patients with bone marrow metastases

Zhou, Min; Wang, Zhi Hong; Zhou, Hong; Liu, Mo; Gu, Yong; Sun, Jun Zhong

doi:10.4103/0973-1482.172717

Cited by 14 publications

(12 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fever without chills was mostly Grades 0–1, accounting for 94.0% of cases. These findings were consistent with those of previous reports 3–6,8–10 . The results of the current study showed that patients with BMM generally had low‐grade fever without chills and normal WBC counts, and those with leukopenia only had a small probability of BMM.…”

Section: Discussionsupporting

confidence: 93%

“…The findings of the current study are consistent with those of previous reports 8,9 . BMM often has no obvious symptoms, unless it causes severe fever, anemia, or bleeding 3–6,8–10 . BC with BMM is not common in clinical practice, and many clinical doctors do not have a clear or comprehensive understanding of the disease.…”

Section: Discussionsupporting

confidence: 90%

“…These findings were consistent with those of previous reports. [3][4][5][6][8][9][10] The results of the current study showed that patients with BMM generally had lowgrade fever without chills and normal WBC counts, and those with leukopenia only had a small probability of BMM. Similarly, low-grade fever was also reported in three previous studies.…”

Section: Characteristicsmentioning

confidence: 93%

See 2 more Smart Citations

Clinicopathological features and prognosis of breast cancer combined with symptomatic bone marrow metastases: A 10‐year, single‐center, real‐world study of 67 cases

Niu

Zhang

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

Purpose Bone marrow metastasis (BMM) is uncommon in breast cancer (BC), and early diagnosis is challenging. BMM lacks definitive treatment options and poses a great threat to the survival of patients. Herein, we investigated the clinical features, prognosis, and factors affecting the prognosis of BC patients with symptomatic BMM to help improve the understanding of this disease and provide effective diagnostic and treatment strategies. Methods Clinical data of 67 patients with BC and BMM were retrospectively analyzed for clinical characteristics, treatment, and prognosis of BMM. Univariate and multivariate analyses were performed to determine factors affecting overall survival following BMM (BMMOS). Results Among patients with BMM, 86.6% were diagnosed after bone metastasis (BM), while 13.4% were diagnosed simultaneously with BM. A total of 73.1%, 13.4%, and 13.4% of the patients had hormone receptor‐positive/human epidermal growth factor 2‐negative (HR+/HER2−) tumors, HER2+ tumors, and triple‐negative tumors, respectively. The most common symptoms of BMM were the coexistence of anemia and thrombocytopenia (26.9%), anemia (19.4%), and pancytopenia (17.9%). The median BMMOS was 7.6 months (95% CI, 3.9–11.3). Univariate and multivariate analyses showed that BMMOS was associated with platelet count <75 × 109/L at the time of BMM diagnosis. The BMMOS of patients who underwent endocrine therapy, combined chemotherapy, and mono‐chemotherapy after BMM was 15.7, 9.7, and 8.6 months, respectively, whereas that of untreated patients was 2.9 months, and the difference among the results was statistically significant (χ2 = 20.102, p < 0.0001). Changes in patient hemogram and/or body temperature during treatment were consistent with the overall effect of the disease (p < 0.0001). Conclusion BMM should be considered in BC patients with BM, an unexplained reduction in hemogram parameters, especially anemia and thrombocytopenia, and/or fever without chills. Active, effective, individualized treatment strategies can prolong BMMOS.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 90%

Section: Characteristicsmentioning

confidence: 93%

See 1 more Smart Citation

Clinicopathological features and prognosis of breast cancer combined with symptomatic bone marrow metastases: A 10‐year, single‐center, real‐world study of 67 cases

Niu

Zhang

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…The most frequent cause of chronic hyponatremia in cancer patients is SIAD, mainly due to ectopic vasopressin secretion by cancer cells [ 50 , 51 , 52 , 53 ]. Several clinical evidences reported hyponatremia as an independent, negative prognostic factor in different types of blood and solid tumors (e.g., lymphoma [ 54 ], gastrointestinal cancers [ 55 , 56 ], hepatocellular carcinoma [ 57 , 58 ], mesothelioma [ 59 ], renal cell carcinoma [ 60 , 61 ], and small cell lung cancer [ 62 , 63 ]), and a concordant improvement of overall and progression-free survival after the appropriate correction of reduced serum [Na + ] [ 24 ], even in patients with extensive and terminal disease [ 64 ]. Accordingly, hyponatremia has been proposed as a biomarker able to identify high-risk subjects affected by lung cancer [ 65 ].…”

Section: Hyponatremia and Healthmentioning

confidence: 99%

“…It is now widely accepted that hyponatremia represents a negative independent prognostic factor in oncologic patients, and is associated with poor progression-free and overall survival in several cancers [ 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 ]. The direct contribution of this electrolyte imbalance (which cannot be considered a mere surrogate marker of the severity of clinical conditions) is supported by the observation that the correction of serum [Na + ] may reduce the overall mortality rate in hyponatremic patients [ 37 ].…”

Section: Non Osmotically-induced Oxidative Stressmentioning

confidence: 99%

Hyponatremia and Oxidative Stress

et al. 2021

View full text Add to dashboard Cite

Hyponatremia, i.e., the presence of a serum sodium concentration ([Na+]) < 136 mEq/L, is the most frequent electrolyte imbalance in the elderly and in hospitalized patients. Symptoms of acute hyponatremia, whose main target is the central nervous system, are explained by the “osmotic theory” and the neuronal swelling secondary to decreased extracellular osmolality, which determines cerebral oedema. Following the description of neurological and systemic manifestations even in mild and chronic hyponatremia, in the last decade reduced extracellular [Na+] was associated with detrimental effects on cellular homeostasis independently of hypoosmolality. Most of these alterations appeared to be elicited by oxidative stress. In this review, we focus on the role of oxidative stress on both osmolality-dependent and -independent impairment of cell and tissue functions observed in hyponatremic conditions. Furthermore, basic and clinical research suggested that oxidative stress appears to be a common denominator of the degenerative processes related to aging, cancer progression, and hyponatremia. Of note, low [Na+] is able to exacerbate multiple manifestations of senescence and to decrease progression-free and overall survival in oncologic patients.

show abstract

Effects of low extracellular sodium on proliferation and invasive activity of cancer cells in vitro

et al. 2019

View full text Add to dashboard Cite

Clinical outcome of 30 patients with bone marrow metastases

Abstract: To make primary origin clear and start systemic antitumor therapy is beneficial for patients with bone marrow metastases.

Cited by 14 publications

References 12 publications

Clinicopathological features and prognosis of breast cancer combined with symptomatic bone marrow metastases: A 10‐year, single‐center, real‐world study of 67 cases

Clinicopathological features and prognosis of breast cancer combined with symptomatic bone marrow metastases: A 10‐year, single‐center, real‐world study of 67 cases

Hyponatremia and Oxidative Stress

Effects of low extracellular sodium on proliferation and invasive activity of cancer cells in vitro

Contact Info

Product

Resources

About